EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Navneet Upadhyay iD, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R Hankosky iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71250 ↗

At a glance

Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Navneet Upadhyay and 5 co-authors. Institution: Eli Lilly and Company, Indianapolis, Indiana, USA. Major MEDLINE topics: Tirzepatide, Health Care Costs, Obesity, Overweight. 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025. Adults > 55 years with obesity, or overweight with ≥ 1 weight‐related comorbidity, without T2 diabetes who initiated tirzepatide for weight management were compared with propensity score‐matched individuals who did not receive any incretin‐based therapies. Changes in all‐cause healthcare costs (excluding tirzepatide; per‐person‐per‐month) between cohorts were assessed at 3–6, 6–12 and 12–18 months using a difference in differences (DiD) framework. Informative censoring and differential follow‐up were addressed with inverse‐probability‐of‐censoring‐weights and pairwise censoring.

Results

Each cohort comprised 15843 individuals. Healthcare cost DiD estimates (95% CI) for the tirzepatide versus control cohorts were −$145 (−266, −25; 12.3% reduction; p = 0.022) during 6–12 months and −$319 (−544, −94; 25.4% reduction; p = 0.015) during 12–18 months; using pairwise censoring, estimates were −$181 (−319, −43; p = 0.021) and −$607 (−1007, −207; p = 0.023), respectively. Cost offsets with tirzepatide were driven by higher medical costs in controls during 12–18 months (−$211 [−$407, −$15]; p = 0.065) and fewer inpatient/emergency department visits with tirzepatide versus controls; incidence rate ratio (95% CI) 0.69 (0.50, 0.94; p = 0.021) during 12–18 months.

Conclusions

Monthly cost offsets for persistent tirzepatide users versus untreated individuals grew over time, offsetting $319 (ranging from $94 to $544) tirzepatide costs by 12–18 months. These results have implications for the $195 monthly net Medicare cost for the Bridge programme, suggesting tirzepatide may generate near‐term cost savings in an older population that stays on treatment.

Subjects

MeSH terms (MEDLINE)

TirzepatideHealth Care CostsObesityOverweightHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPropensity ScoreUnited StatesIncretins

Author keywords

GLP‐1cost‐effectivenesselderlyincretin therapyreal‐world evidenceweight management

Substances

TirzepatideIncretins

Authors and institutions

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Cencora, Conshohocken, Pennsylvania, USA.
  • Aixial Group, Boulogne-Billancourt, France.

ORCID profiles: Navneet Upadhyay, Emily R Hankosky

Funding

  • Eli Lilly and Company

Cite

APA

Upadhyay, N., Bonakdar, A., Subedi, K., Banerjee, S., Behrend, B., & Hankosky, E. R. (2026). Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71250

Vancouver

Upadhyay N, Bonakdar A, Subedi K, Banerjee S, Behrend B, Hankosky ER. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71250

BibTeX
@article{Upadhyay2026,
  author = {Upadhyay, Navneet and Bonakdar, Ali and Subedi, Keshab and Banerjee, Soutrik and Behrend, Benjamin and Hankosky, Emily R},
  title = {Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71250}
}
Start for free →